Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus*,**,★,★★
Section snippets
Patients and methods
We studied 7 patients with SLE and SLS who attended the outpatient departments of St. Thomas' Hospital and the Royal London Hospital between 1984 and 2001, which followed a total of 2650 SLE patients. SLE was diagnosed when a patient had at least 4 of the American College of Rheumatology criteria for classification of SLE (8). Patients with SLS were identified retrospectively through careful examination of patient records in 5 cases and prospectively in 2 cases.
Both clinical and investigation
Case reports
A summary of the salient features of these cases can be found in Tables 2 and 3.
Clinical features
All 7 patients were women, the median age at diagnosis of SLE was 21 years (range, 14-47 years), and the median follow-up was 46 months (range, 84-204 months). The median duration of SLE before the diagnosis of SLS was 60 months (range, 12 to 180 months).
Dyspnea was a presenting feature in all cases, and chest pain was found in 6 patients. Other features of lupus included arthritis/arthralgia in 6 patients and renal disease in 3. There was a history of myositis in 1 patient. Further clinical
Clinical features
The major symptom of SLS is exertional dyspnea of variable severity, progressing over a period of weeks or months to breathlessness at rest. Orthopnea may occur because of diaphragmatic weakness (3). Pleuritic chest pain is reported frequently. In our patients, dyspnea was a universal presenting feature, and chest pain was found in all except 1 patient.
Generally, onset of SLS after diagnosis of SLE varies from 4 months to 24 years (9). However, in 2 cases, SLS was the presenting feature of SLE
Conclusion
Our cases differ in many ways, including the clinical features of underlying SLE, treatments received before and after the diagnosis of SLS, auto-antibody profile, and age at and time of SLS onset after the initial diagnosis of SLE. However, certain similarities are worth highlighting. First, in terms of establishing the diagnosis, the presenting symptoms usually were progressive breathlessness and chest pain. Investigations typically showed reduced lung volumes with no evidence of parenchymal
References (22)
- et al.
Pleuro-pulmonary manifestations of systemic lupus erythematosus
Rheum Dis Clin North Am
(1994) - et al.
Pulmonary manifestations of systemic lupus erythematosus
Clin Chest Med
(1998) - et al.
Shrinking lung syndrome in systemic lupus erythematosus
Mayo Clin Proc
(2000) - et al.
Respiratory muscle dysfunction in systemic lupus erythematosus
Chest
(1983) - et al.
Phrenic nerve function in patients with diaphragmatic weakness and systemic lupus erythematosus
Chest
(1988) Effect of theophylline on diaphragmatic muscle function
Chest
(1987)- et al.
Diaphragm function and lung involvement in systemic lupus erythematosus
Am J Med
(1977) - et al.
Unexplained dyspnoea and shrinking lung in systemic lupus erythematosus
Br Med J
(1965) - et al.
Pleuropulmonary manifestations of systemic lupus erythematosus
Thorax
(2000) - et al.
Shrinking lung in primary Sjögren's syndrome
Arthritis Rheum
(1999)
The 1982 revised criteria for the classification of systemic lupus erythematosus
Arthritis Rheum
Cited by (0)
- *
Mohammed Y. Karim, MA, MSc, MRCP: Lecturer in Immunology, Lupus Research Unit, The Rayne Institute, and Immunology Department, St. Thomas' Hospital, London, UK; Luis C. Miranda, MD: Research fellow, Instituto Português de Reumatologia, Lisbon, Portugal; Colin M. Tench, MD, MRCP: Specialist Registrar in Rheumatology, Department of Rheumatology, The London Hospital, London, UK; Patrick A. Gordon, MRCP: Specialist Registrar in Rheumatology, Lupus Research Unit, The Rayne Institute, London, UK; David P. D'Cruz, MD, FRCP: Consultant Rheumatologist, Lupus Research Unit, The Rayne Institute, London, UK; Munther A. Khamashta, MD, PhD, MRCP: Consultant Physician, Lupus Research Unit, The Rayne Institute, London, UK; Graham R.V. Hughes, MD, FRCP: Consultant Rheumatologist, Lupus Research Unit, The Rayne Institute, London, UK.
- **
There is no declared conflict of interest.
- ★
No financial support was received in respect of this study.
- ★★
Address reprint requests to Mohammed Y. Karim, Department of Immunology, 2nd floor, North Wing, St. Thomas' Hospital, Lambeth Palace Road, London SE1 7EH. E-mail: [email protected]